In this study, we found that MK-2206 can decrease resistance to cisplatin caused by POSTN treatment and the results suggested that POSTN expression in cancer stroma may be an indicator for poor survival and platinum resistance and the use of MK-2206 may be beneficial to augment the efficacy of existing cancer therapeutics. This evidence concerns the gene POSTN and cancer.